Actelion
Also known as: Actelion | ACTELION | Actelion Japan | Actelion Pharmaceuticals Australia Pty. Ltd | Actelion Pharmaceuticals Limited | Actelion Pharmaceuticals U.S., Inc. | Actelion Pharmaceuticals US, Inc | Actelion Pharmaceuticals US, Inc. | ACTELION PHARMS | ACTELION PHARMS LTD
Highest phase reached
Phase 4
First clinical trial
Jan 1, 2002First marketed drug
Nov 20, 2001First NDA
Nov 20, 2001Last known activity
Dec 8, 2023
Timeline
1990s
- Jan 1, 1997
Actelion— Founded
2000s
- Sep 30, 2003
Axovan AG— Acquired
- Nov 20, 2006
CoTherix— Acquired
- Jun 27, 2008
epoprostenol— Marketing Organization
- Jun 27, 2008
epoprostenol— NDA Secondary Org
2010s
- Sep 19, 2013
Ceptaris— Acquired
- Oct 18, 2013
macitentan— NDA Organization
- Jun 16, 2017
Johnson and Johnson— Acquired By
Drugs by trial phase (62 distinct, 210 trials)
Phase 4 (8 own, 1 via acquisition)
Phase 3 (9 own, 0 via acquisition)
Phase 2 (11 own, 3 via acquisition)
Phase 1 (29 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Lung Injury
- Anemia, Sickle Cell
- Apnea
- Asthma
- Clostridium Infections
- Communicable Diseases
- Congenital Abnormalities
- Connective Tissue Diseases
- Cystic Fibrosis
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diarrhea
- Eisenmenger Complex
- Essential Hypertension
- Fabry Disease
- Familial Primary Pulmonary Hypertension
- Fibrosis
- Gangliosidoses
- Gangliosidoses, GM2
- Gaucher Disease
- Glioblastoma
- Graft vs Host Disease
- Heart Defects, Congenital
- Heart Diseases
- Heart Failure
- Hemorrhage
- Hypertension
- Hypertension, Pulmonary
- Hypoplastic Left Heart Syndrome
- Hypoxia
- Idiopathic Pulmonary Fibrosis
- Infections
- Lichen Planus
- Lung Diseases
- Lung Diseases, Interstitial
- Lung Diseases, Obstructive
- Lung Injury
- Lupus Erythematosus, Systemic
- Lymphoma, T-Cell, Cutaneous
- Malaria
- Melanoma
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Mycoses
- Mycosis Fungoides
- Neoplasm Metastasis
- Nervous System Diseases
- Niemann-Pick Diseases
- Niemann-Pick Disease, Type A
- Niemann-Pick Disease, Type C
- Persistent Fetal Circulation Syndrome
- Pick Disease of the Brain
- Pneumonia
- Psoriasis
- Pulmonary Disease, Chronic Obstructive
- Pulmonary Fibrosis
- Raynaud Disease
- Renal Insufficiency
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Respiratory Insufficiency
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Sandhoff Disease
- Sarcoidosis
- Scleroderma, Diffuse
- Scleroderma, Localized
- Scleroderma, Systemic
- Sclerosis
- Skin Ulcer
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Sleep Initiation and Maintenance Disorders
- Subarachnoid Hemorrhage
- Syndrome
- Tay-Sachs Disease
- Tricuspid Atresia
- Ulcer
- Vascular Diseases
- Vasospasm, Intracranial
- Ventricular Dysfunction
- Ventricular Dysfunction, Left
- Ventricular Remodeling
Marketed drugs (6)
Subsidiaries (3 direct, 3 total across the full acquisition tree)
Recent trials (50)
- NCT04914247Study directorN/A—
- NCT04914247Lead sponsorN/A—
- NCT05731492Lead sponsorPhase 1Dec 8, 2023
- NCT05731492Study directorPhase 1Dec 8, 2023
- NCT05433675Lead sponsorPhase 1Jun 22, 2022
- NCT05433675Study directorPhase 1Jun 22, 2022
- NCT05392530Study directorPhase 1May 25, 2022
- NCT05392530Lead sponsorPhase 1May 25, 2022
- NCT05179876Study directorPhase 3May 4, 2022
- NCT05179876Lead sponsorPhase 3May 4, 2022
- NCT05236231Study directorPhase 1Feb 4, 2022
- NCT05236231Lead sponsorPhase 1Feb 4, 2022
- NCT05140525CollaboratorPhase 3Jan 31, 2022
- NCT04963439Study directorPhase 1Jul 8, 2021
- NCT04963439Lead sponsorPhase 1Jul 8, 2021
Details
- Founded
- Allschwil, CH Jan 1, 1997
- First NDA
- Nov 20, 2001
- Last known activity
- Dec 8, 2023
Designations held
- Orphan drug
- Fast track